The Business of Basic Research | GenomeWeb

The New York Times' Nicholas Wade likens NIH's funding of basic research to the management of a stock index fund — "they buy everything in the market, and the few spectacular winners make up for all the disasters." In fact, basic research is so risky, he adds, that only the government is interested in paying for it. "It is a venture that produces far fewer hits than misses," Wade says.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.